Get In Touch
Xeraya Capital Sdn Bhd
26.03–26.08, G Tower
#199 Jalan Tun Razak, KL
+603 2381 8700
Submit a Proposal

Imago BioSciences

Imago Biosciences have recently developed inhibitors of the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a critical role in regulating the growth and development of bone marrow cells. Their first inhibitor of LSD1 called IMG-7289 is being tested in patients with acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis.


Imago's efforts are aimed at improving the management of proliferative diseases of the bone marrow and activation of the immune system.

  • Founded


  • Partnered


  • IPO

    2021 (IMGO)

  • Divested

    2022 (Merck)

Let's talk

Are you the next big thing?

We’re a team of VC/PE who are excited about innovative ideas in life sciences. Submit your proposal to us!